08:23 AM EST, 12/12/2024 (MT Newswires) -- Trevi Therapeutics ( TRVI ) said Thursday that enrollment in its phase 2b study of investigational therapy Haduvio in idiopathic pulmonary fibrosis with chronic cough has reached 75% of the targeted sample size of 160 patients.

The company said an independent data monitoring statistician reaffirmed the sample size of 160 IDF patients with chronic cough following a sample size re-estimation analysis, wherein 80 participants were treated with Haduvio at the highest dose of 108 mg twice daily for six weeks.

Topline results from the trial are still expected in H1 2025, the company added.

Trevi's stock surged 71% in recent Thursday premarket activity.